Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 16004563

Perlegen sciences, inc.

Eric Peacock·Phyllis Whiteley
View original source ↗Export metadata ↓

Abstract

For years we have recognized that using genetics to target the right medicines to the right patients at the right time could improve health care; however, technical and financial constraints have prevented researchers from conducting the comprehensive, whole-genome association studies required to make such advances. Now, Perlegen and its collaborators are making personalized medicine and high density whole-genome association studies a reality. Perlegen quickly and cost-effectively analyzes millions of unique genetic variations in thousands of patients to identify the genetic differences associated with efficacy and side effects. This enables the pharmaceutical drug response to be predicted, and the therapeutic window of a treatment to be expanded. Perlegen licenses compounds that may benefit from this approach, and collaborates with pharmaceutical companies to rescue and better position medicines in their portfolios. Furthermore, the company collaborates with researchers in the public sector to discover the genetic variations associated with common diseases, paving the way for new therapeutics and diagnostics.

Explore related subjects

Drug Delivery SystemsDrug IndustryGenotypePharmacogeneticsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eric Peacock, Phyllis Whiteley. 2005. Perlegen sciences, inc.. https://doi.org/10.1517/14622416.6.4.439

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Microinfusion using hollow microneedles.

PURPOSE: The aim of the study is to determine the effect of experimental parameters on microinfusion through hollow microneedles into skin to optimize drug delivery protocols and identify rate-limiting barriers to flow. METHODS: Glass microneedles were inserted to a depth of 720-1080 microm into human cadaver skin to microinfuse sulforhodamine solution at constant pressure. Flow rate was determined as a function of experimental parameters, such as microneedle insertion and retraction distance, infusion pressure, microneedle tip geometry, presence of hyaluronidase, and time. RESULTS: Single microneedles inserted into skin without retraction were able to infuse sulforhodamine solution into the skin at flow rates of 15-96 microl/h. Partial retraction of microneedles increased flow rate up to 11.6-fold. Infusion flow rate was also increased by greater insertion depth, larger infusion pressure, use of a beveled microneedle tip, and the presence of hyaluronidase such that flow rates ranging from 21 to 1130 microl/h were achieved. These effects can be explained by removing or overcoming the large flow resistance imposed by dense dermal tissue, compressed during microneedle insertion, which blocks flow from the needle tip. CONCLUSIONS: By partially retracting microneedles after insertion and other methods to overcome flow resistance of dense dermal tissue, protocols can be designed for hollow microneedles to microinfuse fluid at therapeutically relevant rates.

Drug Delivery Systems↗
PubMed2006

Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI.

We report the development and in vitro study of a nanoconjugate serving as a targeted magnetic resonance imaging (MRI) contrast enhancement agent for detection of cancer cells overexpressing the folate receptor. The nanoconjugate was synthesized by coating superparamagnetic iron oxide nanoparticles with covalently bound bifunctional poly(ethylene glycol) (PEG), followed by conjugation with folic acid (FA). The specificity of the nanoconjugate targeting cancerous cells was demonstrated by comparative intracellular uptake of the nanoconjugate and PEG-/dextran-coated nanoparticles by human adenocarcinoma HeLa cells. Preferential targeting to cancerous cells was studied by comparing the uptake of the nanoconjugate by HeLa cells and by non-FR expressing osteosarcoma MG-63 cells. Uptake of the nanoconjugate by HeLa cells after 4 h incubation was found to be a 12-fold higher than that of PEG- or dextran-coated nanoparticles as quantified by inductively coupled plasma spectroscopy. A significant negative contrast enhancement was observed with magnetic resonance (MR) phantom imaging for HeLa cells over MG-63 cells, when both were cultured with the nanoconjugate. Specificity of the nanoconjugate for folate receptors was also verified with a competitive inhibition assay, in which HeLa cells were incubated with both NP-PEG-FA and free FA. The bifunctional PEG used has amide linkages within the PEG chains that can form interchain hydrogen bonding, leading to improved stability of the PEG coating. Self-assembled PEG can be controlled at the molecular level and are suitable for nanoscale coatings.

Drug Delivery Systems↗
PubMed2006

Biohybrid nanosystems with polymer nanofibers and nanotubes.

Advanced techniques for the preparation of nanofibers, core shell fibers, hollow fibers, and rods and tubes from natural and synthetic polymers with diameters down to a few nanometers have recently been established. These techniques, among them electro- and co-electrospinning and specific template methods, allow the incorporation not only of semiconductor or catalytic nanoparticles or chromophores but also enzymes, proteins, microorganism, etc., directly during the preparation process into these nanostructures in a very gentle way. One particular advantage is that biological objects such as, for instance, proteins can be immobilized in a fluid environment within these polymer-based nano-objects in such a way that they keep their native conformation and the corresponding functions. The range of applications of such biohybrid nanosystems is extremely broad, for instance, in the areas of biosensorics, catalysis, drug delivery, or optoelectronics.

Drug Delivery Systems↗